Risankizumab Side Effects
Applies to risankizumab: parenteral injection for iv infusion, parenteral injection for sub-q use.
Side effects include:
Adverse reactions (≥1%) in patients with plaque psoriasis and psoriatic arthritis: upper respiratory infection, headache, fatigue, injection site reaction, tinea infection.
Adverse reactions (>3%) in patients receiving induction treatment for Crohn disease: upper respiratory infection, headache, arthralgia.
Adverse reactions (>3%) in patients receiving maintenance treatment for Crohn disease: arthralgia, injection site reaction, abdominal pain, anemia, pyrexia, back pain, arthropathy, urinary tract infection.
For Healthcare Professionals
Applies to risankizumab: intravenous solution, subcutaneous kit, subcutaneous solution.
Gastrointestinal
Common (1% to 10%): Abdominal pain[Ref]
Dermatologic
Common (1% to 10%): Tinea infections (e.g., tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection)
Uncommon (0.1% to 1%): Folliculitis, urticaria
Postmarketing: Eczema, rash[Ref]
Hematologic
Common (1% to 10%): Anemia[Ref]
Hypersensitivity
Hypersensitivity
Common (1% to 10%): Hypersensitivity reactions[Ref]
Immunologic
Very common (10% or more): Immunogenicity (24%), infections (e.g., cellulitis, osteomyelitis, sepsis, herpes zoster) (22%)[Ref]
Local
Common (1% to 10%): Injection site reactions (e.g., bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, irritation, pain, pruritus, reaction, swelling, warmth)[Ref]
Musculoskeletal
Common (1% to 10%): Arthralgia, arthropathy, back pain[Ref]
Nervous system
Common (1% to 10%): Headache (e.g., tension headache, sinus headache, cervicogenic headache)[Ref]
Other
Common (1% to 10%): Fatigue, asthenia, pyrexia[Ref]
Respiratory
Very common (10% or more): Upper respiratory infections (e.g., respiratory tract infection [viral, bacterial, unspecified], sinusitis [including acute], rhinitis, nasopharyngitis, pharyngitis [including viral], tonsillitis) (up to 13%)[Ref]
Frequently asked questions
- Does Skyrizi cause cancer?
- Skyrizi vs Humira for plaque psoriasis - How do they compare?
- Is Skyrizi approved for treating psoriatic arthritis?
- Who makes Skyrizi and where is it made?
- Skyrizi vs Ilumya. What’s the difference?
- What are the new drugs for plaque psoriasis?
More about risankizumab
- Check interactions
- Compare alternatives
- Reviews (46)
- Dosage information
- During pregnancy
- Drug class: interleukin inhibitors
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
References
1. Product Information. Skyrizi (risankizumab). AbbVie US LLC. 2024;SUPPL-32.
2. Product Information. Skyrizi (risankizumab). AbbVie US LLC. 2019.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.